Multiple Sclerosis
Conditions
Keywords
Multiple Sclerosis, Neutralizing antibodies, Safety, Low immunogenicity, interferon, interferon-beta-1a
Brief summary
This study is to find out the safety and effectiveness of Avonex (interferon-beta-1a) Therapy in patients who have developed neutralizing antibodies during previous interferon-beta treatment
Detailed description
This is a multi-centre, prospective, open label, non-comparative phase IV trial. Eligible patients will receive treatment with IFN-beta-1a AVONEX® 30 mcg i.m. once weekly for 12 months.The patients will be examined clinically and NAb titres will be performed at screening and after 12 months. Adverse event source verification will be performed during the documentation period.
Interventions
DRUGlow immunogenic interferon-beta-1a
dosage and frequency as per Biogen Idec protocol
Sponsors
Biogen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Relapsing-remitting MS according to Poser criteria(CDMS or LSDMS)30 or MS according to McDonald criteria * Disability equivalent to an EDSS of 6.0 or less at screening * Neutralizing antibody titre \> 20 and \<500 in two consecutive NAb tests. One must be from before screening * previous treatment with either subcutaneous administered interferon-b-1b (Betaferon®) or interferon-b-1a (Rebif TM) prior to enrolment * A priori has been decided to be treated with AVONEX
Exclusion criteria
* Is NAb positive on AVONEX * History of major depression * Cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (NYHA III or IV), or significant hypertension (BP \> 180/110 mmHg) * Renal insufficiency defined as serum creatinine \> 1.5 times the upper normal reference limit * Any systemic disease that can influence the patient's safety and compliance, or the evaluation of the disability * Women who are pregnant, breast-feeding or have the possibility for pregnancy during the trial. To avoid pregnancy, women have to be postmenopausal, surgical sterile, sexually inactive or practice reliable contraceptives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| neutralizing antibody levels will be followed | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with NAb positive titre > 20. | 12 months |
| Relative change from baseline (screening) of NAb titre | 12 months |
| Change in the annualised relapse rate and number of relapse-free (total and documented relapses) patients | 12 months and as needed for relapses |
| The percentage of patients with a loss of disability of 1.0 (or more) score on the EDSS. | 12 months |
Countries
Sweden
Outcome results
None listed